Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

BUY
$3.45 - $14.99 $35,507 - $154,277
10,292 New
10,292 $39,000
Q3 2021

Nov 05, 2021

SELL
$14.91 - $21.31 $241,392 - $345,008
-16,190 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$23.16 - $28.08 $374,960 - $454,615
16,190 New
16,190 $395,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $532M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Penn Mutual Asset Management, LLC Portfolio

Follow Penn Mutual Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Penn Mutual Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penn Mutual Asset Management, LLC with notifications on news.